Phase 2 overall response and PFS by group/indication
| Response . | Group 1, DLBCL . | Group 2, FL . | Group 3 . | |||
|---|---|---|---|---|---|---|
| De novo (n = 17) . | Transformed (n = 6) . | (n = 21) . | CLL/SLL (n = 11) . | MCL (n = 9) . | Other (n = 4) . | |
| CR, n | 1 | 0 | 0 | 0 | 0 | 0 |
| PR, n | 3 | 1 | 2 | 6 | 1 | 0 |
| SD, n | 2 | 2 | 11 | 2 | 4 | 1 |
| PD, n | 8 | 3 | 7 | 3 | 4 | 2 |
| Not evaluable, n | 3 | 0 | 1 | 0 | 0 | 1 |
| ORR (CR + PR), n (%) | 4 (23.5%) | 1 (16.7%) | 2 (9.5%) | 6 (54.5%) | 1 (11.1%) | 0 |
| CR + PR + SD, n (%) | 6 (35.3%) | 3 (50.0%) | 13 (61.9%) | 8 (72.7%) | 5 (55.6%) | 1 (25.0%) |
| PFS, mo (95% CI) | —* | —* | 4.6 (2.0-8.3) | 6.4 (2.2-7.1) | 3.8 (1.9-4.6) | 1.9 (1.8-N/A) |
| Response . | Group 1, DLBCL . | Group 2, FL . | Group 3 . | |||
|---|---|---|---|---|---|---|
| De novo (n = 17) . | Transformed (n = 6) . | (n = 21) . | CLL/SLL (n = 11) . | MCL (n = 9) . | Other (n = 4) . | |
| CR, n | 1 | 0 | 0 | 0 | 0 | 0 |
| PR, n | 3 | 1 | 2 | 6 | 1 | 0 |
| SD, n | 2 | 2 | 11 | 2 | 4 | 1 |
| PD, n | 8 | 3 | 7 | 3 | 4 | 2 |
| Not evaluable, n | 3 | 0 | 1 | 0 | 0 | 1 |
| ORR (CR + PR), n (%) | 4 (23.5%) | 1 (16.7%) | 2 (9.5%) | 6 (54.5%) | 1 (11.1%) | 0 |
| CR + PR + SD, n (%) | 6 (35.3%) | 3 (50.0%) | 13 (61.9%) | 8 (72.7%) | 5 (55.6%) | 1 (25.0%) |
| PFS, mo (95% CI) | —* | —* | 4.6 (2.0-8.3) | 6.4 (2.2-7.1) | 3.8 (1.9-4.6) | 1.9 (1.8-N/A) |
SD indicates stable disease; PD, progressive disease; and —, not applicable.
DLBCL combined was 2.7 (1.3-4.5).